Retina

Prof Loewenstein and a cohort of colleagues assessed the current treatment outlook for patients with diabetic retinopathy

LuxIA is designed to screen adult diabetic patients for more-than-mild diabetic retinopathy.

Topcon Healthcare has appointed Daniela Ferrara, MD, PhD, as chief medical officer to lead the company’s clinical and medical strategy

The US FDA recently approved revakinagene taroretcel-lwey (ENCELTO) for the treatment of idiopathic macular telangiectasia type 2 (MacTel)

The US Food and Drug Administration did not identify any safety or efficacy issues associated with aflibercept 8 mg

The study aimed to clarify how race affects visual outcomes for patients with diabetic macular oedema treated with ranibizumab

The phase 3 LUCERNE and TENAYA trials suggested that faricimab may allow clinicians to extend the interval between injections to up to 16 weeks after an initial loading phase

In an established animal model of age-related macular degeneration, Eleva’s recombinant human CPV-104 improved two hallmarks of the disease

Alcon acquired the historic ophthalmic instrument company in 2000

Bangalore-based Eyestem will share more research findings on Eyecyte-RPE at this year's Association for Research in Vision and Ophthalmology meeting

The company's therapeutic candidates include a bispecific antibody to target vascular retinal diseases

In the European Union and the United Kingdom, aflibercept 8 mg (Eylea HD in the US) is currently approved for neovascular age-related macular degeneration and diabetic macular oedema

Fundus images of diabetic retinopathy were assessed by general ophthalmologists, retina specialists and the Aireen artificial intelligence system

Treatment regimens with long-duration therapies continue to be a conversation starter among retina specialists

The Congress on Controversies in Ophthalmology highlights debates, but also discussions

Retina topics serve as the backbone of the scientific programme at this year’s Congress on Controversies in Ophthalmology

Regulatory agencies issued approvals for new treatments and expanded uses of existing therapies in the retina space

Both trials failed to meet their primary endpoints for treatment of age-related macular degeneration

This year, the COPHy meeting moves beyond retina, addressing uveitis, neuro-ophthalmology and glaucoma in Seville, Spain

Researchers assessed the costs to patients and caregivers in Germany, Bulgaria and the US

The approval makes ILM-Blue the first DORC posterior dye product available in China, according to a press release from Zeiss

The authors examined vascular and neural structures in the eye, assessing the foveal avascular zone and choroidal thickness

The synthetic opsin was packaged into an optimised AAV2 gene therapy vector that targets human retinal bipolar cells.

The partnership will use ocular imaging to build an AI foundation model and identify new genetic targets for degenerative diseases